Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05318222 · ClinicalTrials.gov registry record · NA

Genetic Inclusion by Virtual Evaluation

A NA study of Neurodevelopmental Disorders and Birth Defects, sponsored by Baylor College of Medicine.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT05318222 is a NA study of Neurodevelopmental Disorders and Birth Defects that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 200 participants, below the 574-participant average among 27 other Neurodevelopmental Disorders trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05318222, a NA study of Neurodevelopmental Disorders and Birth Defects, is actively recruiting participants, sponsored by Baylor College of Medicine.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This study aims to transform the current clinical practice paradigm by leveraging an internally designed web-based model of delivery of care called Consultagene to provide remote evaluation and genomic sequencing for improving genetic health of less resourced children with rare disorders living along the Texas-Mexico border.

Interventions

  • DIAGNOSTIC_TEST Whole genome sequencing (WGS)

Study Locations (1)

Texas

  • University of Texas Rio Grande Valley - Edinburg

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2022-06-01
Est. Completion 2027-01-31
Phase NA

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT05318222

The ClinicalTrials.gov registry entry for NCT05318222 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 574-participant average among 27 other Neurodevelopmental Disorders trials with a reported enrollment target (65% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Neurodevelopmental Disorders appearing as the primary indexed condition, and to 1 intervention - of which Whole genome sequencing (WGS) is the first listed.

NCT05318222 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05318222 about?

NCT05318222 is a clinical study titled "Genetic Inclusion by Virtual Evaluation". This study aims to transform the current clinical practice paradigm by leveraging an internally designed web-based model of delivery of care called Consultagene to provide remote evaluation and genomic sequencing for improving genetic health of less resourced children with rare disorders living alon...

What is the current status of trial NCT05318222?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2022-06-01. Estimated completion is 2027-01-31.

What conditions does trial NCT05318222 study?

This clinical trial studies the following conditions: Neurodevelopmental Disorders, Birth Defects, Multiple Congenital Anomaly.

What interventions are being tested in trial NCT05318222?

The interventions under investigation include: Whole genome sequencing (WGS) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05318222?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05318222 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurodevelopmental Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.